en
Scientific article
Open access
English

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV

Published inBMC Cancer, vol. 20, no. 1, 886
Publication date2020
Abstract

Despite obvious advances over the last decades, locally advanced adenocarcinomas of the gastroesophageal junction (GEJ) still carry a dismal prognosis with overall 5-year survival rates of less than 50% even when using modern optimized treatment protocols such as perioperative chemotherapy based on the FLOT regimen or radiochemotherapy. Therefore the question remains whether neoadjuvant chemotherapy or neoadjuvant radiochemotherapy is eliciting the best results in patients with GEJ cancer. Hence, an adequately powered multicentre trial comparing both therapeutic strategies is clearly warranted.

Keywords
  • FLOT
  • Locally advanced adenocarcinoma of the gastroesophageal junction
  • Neoadjuvant radiochemotherapy
  • Perioperative chemotherapy
Citation (ISO format)
LORENZEN, Sylvie et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. In: BMC Cancer, 2020, vol. 20, n° 1, p. 886. doi: 10.1186/s12885-020-07388-x
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1471-2407
128views
42downloads

Technical informations

Creation01/14/2021 11:58:00 AM
First validation01/14/2021 11:58:00 AM
Update time03/16/2023 12:18:56 AM
Status update03/16/2023 12:18:55 AM
Last indexation02/12/2024 12:03:50 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack